Cercare Medical

Cercare Medical operates at the intersection of clinical decision-support software, medical imaging, and neurovascular diagnostics. Its core differentiation is a unified, vendor-agnostic platform that processes CT, cone-beam CT, and MRI perfusion studies, rather than focusing on a single modality. The company’s vascular-model approach extends beyond conventional blood-flow measurements by generating biomarkers such as cerebral blood flow, cerebral blood volume, mean transit time, oxygen extraction fraction, and cerebral metabolic rate of oxygen. Its product range spans routine and advanced stroke assessment, including infarct-core and hypoperfusion quantification, ASPECTS, large-vessel occlusion, and intracranial hemorrhage modules, as well as neuro-oncology and neurodegenerative applications. Cercare’s commercial profile is that of a specialized, research-led European health technology company rather than a broad hospital software conglomerate. Public information does not provide a validated competitor set, so direct peer ranking is not reliable. Its more than 30-country footprint, multiple regulatory clearances, scientific founding team, and 2026 Siemens Healthineers collaboration are stronger indicators of market access than company scale alone. The main strategic challenge is converting technical breadth and clinical evidence into sustained hospital adoption.

Cercare Medical’s trajectory shows a gradual transition from research-founded imaging software company to an internationally distributed clinical technology business. Founded in 2013 under the name Combat Stroke, it initially centered on acute stroke management and automated CT and MRI perfusion analysis. A €50,000 grant recorded in February 2017 and an additional €1.8 million EU grant recorded in May 2019 indicate early non-dilutive support, although the historical funding timeline contains inconsistencies. The major financial inflection point came in March 2025 with a €7.4 million venture round led by West Hill Capital. Product development accelerated during the same period: NeuroSuite Version 17 launched in June 2025, followed by a cone-beam CT perfusion solution showcased at RSNA in November 2025. Regulatory clearance in South Korea and a local distribution partnership broadened geographic reach, while the company reported use in more than 30 countries. The May 2026 global collaboration with Siemens Healthineers is the strongest signal of enterprise-scale commercialization. Headcount remains in the 11–50 employee range, suggesting growth is being pursued through partnerships and distribution as well as direct hiring.